Search academic texts

Information × Registration Number 0224U000148, 0122U000545 , R & D reports Title To study the effectiveness of combination therapy with first- and second-line drugs and to develop optimal treatment regimens for patients with refractory sarcoidosis popup.stage_title Head Havrysiuk Volodymyr K., д.мед.н. Registration Date 03-01-2024 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  Refractory pulmonary sarcoidosis, effectiveness of therapy with methotrexate (MTX) and hydroxychloroquine (HQ) or methotrexate and pentoxifylline (P) Study object – 38 patients: 18 – corticosteroid-refractory and 20 – methotrexate-refractory pulmonary sarcoidosis. Aim of study – to create the optimal regimens of treatment of patients with refractory pulmonary sarcoidosis based on the study of effectiveness and tolerability of combination first and second-line medications and assessment of long-term outcomes of therapy. Methods – clinical, laboratory, lung computed tomography (CT), lung function and diffusion lung capacity tests. It was established that MTX+methylprednisolone combination in patients with corticosteroid-refractory pulmonary sarcoidosis was highly effective: clinical remission and CT normalization was observed in 66.7 % of cases. At the same time, in 33.3 % of patients there was no effect of this treatment, meaning that along with corticosteroid-resistance the MTX-resistance had been present as well. It was found out that in MTX+P group 3 months therapy led to initial clinical remission and CT improvement only in 1 case, in 75 % of cases – clinical remission was not achieved. In 1 case the therapy was discontinued because of serious adverse event. It was revealed that MTX+HQ combination was significantly more effective: CT-confirmed regression of sarcoidosis was registered in 66.7 % of patients, stabilization - in 16.7 % of patients, in 16,7 % (2 cases) – serious adverse reactions causing discontinuation of drugs. According to preliminary data in 1 out of 5 patients 6 months after completion MTX+HQ treatment a relapse of the disease occurred. There was developed a technology of management of patients with pulmonary sarcoidosis, which increases the efficacy of diagnosing and individualized therapy by 15, 0 % and reduce the rate of adverse effects of therapy by 17 %. Application sphere – pulmonology, phthisiology. Product Description popup.authors Havrysiuk Volodymyr K Dziublyk Yaroslav О Merenkova Ievgeniia O. Morsʹka Nataliya D Pendalchuk Nataliia V Yachnyk Anatolii I. popup.nrat_date 2024-01-03 Close